Clough Capital Partners L P Bei Gene, Ltd. Transaction History

Clough Capital Partners L P

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 17, 2020	SELL	$189.18 - $286.44 $1.87 Million - $2.82 Million	-9,860 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$123.9 - $195.41 $306,033 - $482,662	-2,470 Reduced 20.03%	9,860 $1.86 Million
Q1 2020 May 15, 2020	SELL	$121.84 - $173.19 $7.41 Million - $10.5 Million	-60,790 Reduced 83.14%	12,330 $1.52 Million
Q4 2019 Feb 14, 2020	SELL	$115.78 - $208.34 $3.42 Million - $6.15 Million	-29,510 Reduced 28.75%	73,120 $12.1 Million
Q3 2019 Nov 14, 2019	BUY	$120.61 - $148.29 $1.43 Million - $1.76 Million	11,870 Added 13.08%	102,630 $12.6 Million
Q2 2019 Aug 14, 2019	BUY	$113.99 - $146.86 $4.91 Million - $6.32 Million	43,050 Added 90.23%	90,760 $11.3 Million
Q1 2019 May 15, 2019	SELL	$122.82 - $151.83 $2.92 Million - $3.61 Million	-23,800 Reduced 33.28%	47,710 $6.3 Million
Q4 2018 Feb 14, 2019	BUY	$107.01 - $175.15 $7.65 Million - $12.5 Million	71,510 New	71,510 $10 Million

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.7B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Clough Capital Partners L P, based on Form 13F filings with the SEC.

Stay updated on Clough Capital Partners L P with notifications on news.